Amneal Pharmaceuticals (AMRX) revenue and earnings history
Amneal Pharmaceuticals reported revenue of $3.02B for fiscal 2025 (year ended Dec 31, 2025), +8.0% on the year before, and net income of $72.1M.
Over 9 years, from fiscal 2016 to fiscal 2025, revenue grew at a compound rate of +12.8% a year.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $3.02B+8.0% | $394M | $72.1M | $340M | $70.1M | $270M | $32M | — | — | $282M | $2.57B | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Amneal Pharmaceuticals (AMRX) on OQRO.
Common questions
What was Amneal Pharmaceuticals's revenue in fiscal 2025?
$3.02B for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 27, 2026. That is +8.0% on fiscal 2024 ($2.79B).
How fast has Amneal Pharmaceuticals's revenue grown?
From $1.02B in fiscal 2016 to $3.02B in fiscal 2025: a compound annual growth rate of +12.8% over 9 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Amneal Pharmaceuticals tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
